In agreement with our findings on the LUAD caused by the EGFR tumor‐driving mutation, HCI‐2509 treatment of C57BL/6N(KRAS G12V) mice resulted a significant increase of H3K4me2 levels, whereas H3K9me2 levels were unaffected (Figs 4E and S4E). Here, KRAS is linked to neoplasm.